Correction: Alexandre-Gouabau et al. “Comprehensive Preterm Breast Milk Metabotype Associated with Optimal Infant Early Growth Pattern”, Nutrients, 2019, 11, 528
,
,
,
,
,
,
,
,
…
1
INRA, UMR1280, Physiopathologie des Adaptations Nutritionnelles, Institut des maladies de l’appareil digestif (IMAD), Centre de Recherche en Nutrition Humaine Ouest (CRNH), F-44093 Nantes, France
2
Service de Pharmacologie et d’Immunoanalyse, Laboratoire d’Etude du Métabolisme des Médicaments, CEA, INRA, Université Paris Saclay, MetaboHUB, F-91191 Gif-sur-Yvette, France
3
LUNAM Université, ONIRIS, Laboratoire d’Etude des Résidus et Contaminants dans les Aliments (LABERCA), USC INRA 1329, F-44307 Nantes, France
4
CHU, Centre Hospitalo-Universitaire Hôtel-Dieu, F-44093 Nantes, France
The authors wish to make a correction to Section 2.7 and Table 4 in the published version of their paper [1].
Table 4.
Major Human Milk Oligosaccharides HMOs detected in breast milk glycome and provided to preterm infants with “faster” or “slower” growth during the W2 to W4 lactation period.
A reverse digit error was found when reporting the monosaccharide compositions of Human Milk Oligosaccharides (HMOs) in Table 4 and, in particular, in the order of hexose (Hex), N-acetylhexosamine (HexNac), fucose (Fuc), and N-acetylneuraminic acid (NeuAc) numbers in the first 12 HMOs. A corrected version of Table 4 is shown below.
One edit to the sentence in the paragraph of 2.7. Lipidomic, Metabolomic, and Glycomic Data Treatment and Metabolites Annotation is needed: “When it was not possible to clearly determine HMO structures, HMOs were named according to their monosaccharide compositions and denoted as hexose (Hex), fucose Fuc), N-acetylhexosamine (HexNac), and N-acetylneuraminicacid (NeuAc) numbers”. This sentence should now read: “When it was not possible to clearly determine HMOs structures, HMOs were named according to their monosaccharide compositions and denoted as hexose (Hex), N-acetylhexosamine (HexNAc), fucose (Fuc), and N-acetylneuraminic acid (NeuAc) numbers”.
This change does not affect anything in the overall results of the selection of HMO biomarkers of infant early growth.
The authors would like to apologize for any inconvenience caused to readers by these changes.
Conflicts of Interest
No funder/sponsor had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Table 4.
Major Human Milk Oligosaccharides HMOs detected in breast milk glycome and provided to preterm infants with “faster” or “slower” growth during the W2 to W4 lactation period.
Table 4.
Major Human Milk Oligosaccharides HMOs detected in breast milk glycome and provided to preterm infants with “faster” or “slower” growth during the W2 to W4 lactation period.
HMOs
Composition
Median (25% and 75% Percentile) from W2 to W4 (Secretors and Non-Secretor Mothers)
Mann–Whitney p-value (FDR-Corrected MW q-Value in Exposant)
VIP–PLS-DA (C1–C2)
MLR p-Value (FDR-Corrected MLR q-Value in Exposant)
mz
RT
Hex
HexNAc
Fuc
NeuAc
“Slower” Growth (n = 38)
“Faster” Growth (n = 29)
Secretors and Non-Secretors
Secretors Only
Secretors and Non-Secretors
Secretors Only
Secretors and Non-Secretors
Secretors Only
Fucosylated
61.46 (50.28–65.13)
62.82 (60.20–65.19)
0.1847 t
0.1370
0.73
Sialylated
8.47 (6.97–9.40)
7.45 (6.70–9.11)
0.2545
0.2773
0.37
Fucosylated./Sialylated
1.95 (1.50–2.32)
1.63 (1.33–2.30)
0.0973 t
0.1422
0.35
Neutral
28.30 (26.78–38.23)
26.87 (25.92–29.57)
0.0352 *
0.6966
0.95
Mono Fucosylated
28.49 (19.06–34.74)
36.95 (31.83–39.21)
0.0020
0.0669
0.19
Di Fucosylated
26.64 (23.83–28.53)
23.12 (19.14–26.77)
0.0026
0.0054 *
0.10
Tri Fucosylated
3.52 (2.96–4.00)
2.85 (2.63–3.26)
0.0061
0.0883
0.43
Tetra Fucosylated
3.20 (2.54–4.07)
2.94 (1.77–3.83)
0.1520
0.0243 *
0.004 *
LNFPI≠
856.3280
10.2
3
1
1
0
11.99 (0.36–18.65)
19.86 (15.00–23.69)
0.0003 **
0.0045 *
1.22
1.26
0.63
0.03 *
pLNH≠
1075.4023
18
4
2
0
0
0.26 (0.14–0.35)
0.38 (0.26–0.54)
0.0014 **
0.0013 *
1.44
1.75
0.50
0.10 *
2′-FL≠
491.1958
8.5
2
0
1
0
11.22 (0.10–13.87)
12.58 (10.29–15.09)
0.0882 t
0.9433
1.10
1.08
0.63
0.22 *
6′-SL
636.2333
9.6
2
0
0
1
2.50 (2.30–3.06)
2.47 (1.81–3.05]
0.3219
0.9433
0.65
0.29
0.26
0.31 *
LNnH≠
1075.4023
15.1
4
2
0
0
0.82 (0.32–1.44)
0.95 (0.58–2.31)
0.0689 t
0.8116
1.25
1.22
0.67
0.52 t
LNT/LNnT≠
710.2701
10.9
3
1
0
0
22.52 (20.29–35.65)
22.46 (20.04–25.21)
0.1991 t
0.2591
1.00
0.81
0.48
0.62 t
LSTc/b
1001.3655
18.4
3
1
0
1
2.59 (2.00–3.57)
2.63 (2.25–3.41)
0.7012
0.1422
0.89
0.87
0.78
0.65 t
LNDFH I
1002.3859
5.7
3
1
2
0
4.26 (0.44–6.25)
5.10 (0.51–6.96)
0.3986
0.8903
0.55
0.74
0.22
0.50 t
3′ FL
491.1958
1.8
2
0
1
0
0.03 (0.00–0.08)
0.00 (0.00–0.03)
0.0133 *
0.1697
0.94
0.70
0.12
0.09 *
3′ SL
636.2333
18.9
2
0
0
1
0.15 (0.13–0.21)
0.14 (0.11–0.18)
0.1555 t
0.9433
0.46
0.48
0.26
0.16 *
LNDFH ≠
1002.3859
9.6
3
1
2
0
0.26 (0.14-0.36)
0.36 (0.27-0.45)
0.0020 **
0.1050
1.12
1.05
0.43
0.04 *
LNDFHx
1002.3859
6.8
3
1
2
0
0.26 (0.11–1.11)
0.14 (0.07–0.24)
0.0293 *
0.0726 t
0.97
1.04
0.15
0.06 *
4230c≠
1513.5760
13.5
4
2
3
0
0.11 (0.00–0.18)
0.07 (0.04–0.14)
0.5405
0.0002 **
1.90
1.55
0.0062 *
0.07 *
4210d≠
1221.4602
17.4
4
2
1
0
0.18 (0.00–0.39)
0.47 (0.27–1.31)
0.0005 **
0.0142 *
1.69
1.66
0.10
0.04 *
4220e≠
1367.5181
13
4
2
2
0
1.59 (0.37–2.43)
1.75 (1.35–2.77)
0.1799 t
0.6128
1.28
1.76
0.86
0.78 t
4230b≠
1513.576
8.2
4
2
3
0
0.65 (0.00–1.49)
0.61 (0.06–1.20)
0.7967
0.0893 t
1.38
1.33
0.0095 *
0.09 *
3000≠
507.1907
6.4
3
0
0
0
0.26 (0.19–0.31)
0.16 (0.12–0.23)
<0.0001 ***
0.0022 *
2.06
0.90
0.53
0.22 *
5300 (2+)
720.7709
18.1
5
3
0
0
0.15 (0.10–0.23)
0.16 (0.14–0.32)
0.0771 t
0.6305
1.41
1.39
0.72
0.37 *
6420c (2+)≠
1049.3949
18.1
6
4
2
0
0.44 (0.09–0.64)
0.50 (0.32–0.72)
0.1893 t
0.5220
1.11
0.67
0.30
0.76 t
6430d (2+)≠
1122.4238
16.8
6
4
3
0
0.14 (0.00–0.26)
0.15 (0.10–0.24)
0.2102 t
0.2663
1.18
1.00
0.34
0.87 t
5310c
1586.5924
18
5
3
1
0
0.29 (0.22–0.38)
0.38 (0.25–0.46)
0.0428 *
0.4094
0.90
1.02
0.95
0.16 *
2110a
694.2752
3.6
2
1
1
0
0.01 (0.00–0.27)
0.24 (0.00–0.51)
0.0811 t
0.6772
0.90
1.49
0.48
0.60 t
4240b≠
1659.6339
13.9
4
2
4
0
0.04 (0.00–0.11)
0.04 (0.00–0.08)
0.9654
0.0457 *
1.29
0.68
0.0007 **
0.05 *
2020a≠
637.2537
11.1
2
0
2
0
0.49 (0.04–0.61)
0.55 (0.45–0.66)
0.0840 t
0.9700
1.10
1.23
0.72
0.20 *
5310b
1586.5924
17
5
3
1
0
0.24 (0.13–0.31)
0.16 (0.09–0.27)
0.1091 t
0.0420 *
0.93
0.97
0.84
0.40 *
4220a
684.2627
7.7
4
2
2
0
0.20 (0.14–0.29)
0.11 (0.07–0.25)
0.0216 *
0.0911 t
0.49
0.52
0.10
0.82 t
4220b≠
1367.5181
8.8
4
2
2
0
0.31 (0.09–1.78)
0.23 (0.07–0.33)
0.0895 t
0.3352
1.02
0.99
0.15
0.14 *
4210b≠
1221.4602
12.6
4
2
1
0
7.19 (5.03–8.90)
3.75 (2.37–6.33)
<0.0001 ***
0.0003 **
1.05
1.84
0.30
0.07 *
5330b
1878.7082
13.9
5
3
3
0
0.23 (0.00–0.39)
0.29 (0.00–0.38)
0.3749
0.4106
0.96
1.10
0.05
0.26 *
5320a
1732.6503
12.9
5
3
2
0
0.27 (0.13–0.70)
0.13 (0.05–0.22)
0.0004 **
0.0045 *
1.06
1.37
0.47
0.16 *
Relative HMO abundances (%) were calculated by dividing absolute HMO peak area by each sample’s total HMO peak areas. Values are medians (25% and 75% percentiles) from relative HMOs abundances from week 2 to week 4 of lactation period. P-values for comparison between “faster” and “slower” growth groups were derived by using Mann–Whitney U test. Variables were considered significantly modified between the two groups of infants’ growth when their multiple comparisons adjusted p-values (e.g., q-value after False Discovery Rate (FDR)) was <0.05. *: FDR-corrected MW q-value < 0.05; **: FDR-corrected MW q-value < 0.01; ***: FDR-corrected MW q-value < 0.001; t: FDR-corrected MW q-value < 0.1. Multiple Linear Regression (MLR) for infant weight Z-score (p-value) was also combined with FDR and predictive ability for infant weight growth were considered reliable when MLR q-value was <0.05. *: FDR-corrected MLR q-value < 0.05; t: FDR-corrected MLR q-value < 0.1. ≠: variables of importance for Partial Least Square-Discriminant Analysis (PLS-DA) model (VIP > 1.0). LNDFH, Lacto-N-difucosyl-hexaose; LNT, lacto-N-tetraose; pLNH, p-Lacto-N-Hexaose; LNFP, lacto-N-fucopentaose; LNnT, lacto-N-neotetraose; LNT, lactoN-tetraose; LST, sialyl-lacto-N-tetraose; 2′-FL, 2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; Hex, hexose; HexNac, N-acetylhexosamine; Fuc, fucose and NeuAc, N-acetylneuraminic acid. Fucosylation was further investigated to determine difference in abundance of mono, di, tri, and tetrafucosylation (based on the number of fucose residues).
